stockrowSpero Therapeutics, Inc.
SPROSpero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024.
- Revenue
- −95.6%
- EPS
- −433.3%
- Free cash flow
- +69.7%
Quarter to June 2026, against a year earlier
Follow SPRO
Alert me
Spero Therapeutics, Inc. (SPRO) Return on invested capital
Spero Therapeutics, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 21.0 percentage points from fiscal 2025 (21.0%). Over the past ten years it has ranged from −6,493.6% (fiscal 2018) to 43.9% (fiscal 2023); the current reading is higher than 91% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 21.0% | 21.04 |
| FY2024 | 0.00% | (43.93) |
| FY2023 | 43.9% | 43.93 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 963.10 |
| FY2020 | −963.1% | (963.10) |
| FY2019 | 0.00% | 6,493.63 |
| FY2018 | −6,493.6% | (6,493.63) |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | 0.00% |
| CLNN Clene Inc. compare | 0.00% |
| CING Cingulate Inc. compare | 0.00% |
| CRDF Cardiff Oncology, Inc. compare | 0.00% |
| GOSS Gossamer Bio, Inc. compare | 0.00% |
| SPRO Spero Therapeutics, Inc. | 0.00% |
| NORD Nordicus Partners Corporation compare | −4.43% |
| FBIO Fortress Biotech, Inc. compare | −41.3% |
| XBIT XBiotech Inc. compare | −159.2% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)